Study analysis · The American journal of clinical nutrition · 2005
30g of resistant starch a day improved insulin sensitivity by 33%—but that's a relative number from just 10 people over 4 weeks, and the full paper isn't available.
In a tiny 4-week study, healthy adults who took 30 grams of resistant starch daily had better lab measures of how well insulin works, but we don't know if that translates to real health benefits.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study tested whether eating resistant starch changes how well the body uses insulin. It was a small experiment with 10 healthy people, but because we don't know if people were randomly assigned to treatments, we can only say it might be linked to better insulin sensitivity, not that it definitely causes it.
What’s the bottom line?
In a small 4-week study, healthy adults took 30 grams of resistant starch daily or a placebo. Resistant starch seemed to improve how well insulin helped clear sugar.
How strong is this study?
The study used good tests to measure insulin sensitivity, but it only included 10 people for 4 weeks, and we don't have all the details about how it was run. That means the results are interesting but not strong enough to trust completely.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
32 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=10)+1.0/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 537 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. Randomization and blinding are not explicitly stated in the abstract. The study is small (n=10), short (4 weeks), and abstract-only, so confounding cannot be ruled out. Therefore, cause-effect relationships cannot be established.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding statement was present in the provided text, so potential conflicts cannot be assessed.
The provided text is an abstract without a COI or funding declaration; no author affiliations or disclosures are included.
Key takeaways
- 01
Clamp insulin sensitivity was higher with resistant starch: 9.7 vs 8.5 (absolute difference 1.2 x 10^-2 units; P=0.03).
- 02
Meal-test insulin sensitivity was 33% higher relative (P=0.05).
- 03
Insulin-adjusted glucose clearance was 44% higher relative (P=0.03).
- 04
Fasting ghrelin was higher (2769 vs 2062 pg/mL; P=0.03).
- 05
This was a 4-week study in only 10 healthy people, so the results are preliminary.
- 06
The absolute difference in clamp insulin sensitivity was 1.2 x 10^-2 units, but the study did not report how this changes a person's absolute risk of diabetes or other outcomes.
- 07
The 33% and 44% figures are relative differences, not absolute risk reductions.
- 08
The clinical importance is unclear from the abstract.
Practical takeaways
No dietary change can be confidently recommended from this abstract alone. If you're considering resistant starch supplements for metabolic health, discuss it with a clinician—especially if you take diabetes medication.
Based on a 4-week study in only 10 healthy adults; randomization and blinding are not specified in the abstract; full methodology and absolute clinical benefit are not available.
low confidenceWhen you see a nutrition headline with a percentage, ask: relative or absolute? This study's 33% and 44% are relative differences in lab measures, not absolute risk reductions.
The abstract does not report absolute risk changes or clinical outcomes like diabetes diagnosis.
low confidenceWhy this study matters
Tiny trial, big caveats: n=10 for 4 weeks
The study gave 10 healthy subjects either 30 g/day resistant starch or placebo for 4 weeks. Clamp-derived insulin sensitivity was higher with resistant starch: 9.7 vs 8.5 x 10^-2 mg glucose/kg/min per mU insulin/L, an absolute difference of 1.2 x 10^-2 units (P=0.03). Randomization and blinding are not specified in the abstract, and full methodology is unavailable.
A sample of 10 is extremely small, so one or two unusual responses could drive the result. It's a reminder that promising nutrition headlines often come from early, fragile studies.
Relative vs absolute: 33% and 44% are not risk reductions
During a meal tolerance test, insulin sensitivity was 33% higher relative with resistant starch (P=0.05), and insulin-adjusted forearm muscle glucose clearance was 44% higher relative (P=0.03). These are relative differences in laboratory measures, not absolute reductions in diabetes risk. The abstract does not report absolute clinical risk reduction.
Headlines often say '33% better' without clarifying it's relative. The absolute benefit could be tiny or unknown, especially in healthy people over only 4 weeks.
Muscle pulls more glucose with less insulin
Forearm muscle glucose clearance during the meal test was higher after resistant starch (P=0.03) even though insulin concentrations were lower (P=0.02). After adjusting for insulin, glucose clearance was 44% higher relative.
It suggests the muscle became more sensitive to insulin's signal—more sugar cleared with less insulin. That's the kind of mechanism people care about for metabolic health.
Fat tissue release changes, but blood NEFA doesn't
Subcutaneous abdominal adipose tissue NEFA release was lower (P=0.02) and glycerol release was lower (P=0.05) with resistant starch, yet systemic NEFA concentrations were not significantly altered. This suggests a tissue-specific effect that may not show up in a standard blood test.
It hints that resistant starch may change how fat tissue behaves locally, even if whole-body blood markers look unchanged. That's a nuance most headlines miss.
Gut metabolites up, hunger hormone also up
Short-chain fatty acids were higher during the meal test (acetate P=0.05; propionate P=0.01), and adipose acetate uptake was higher (P=0.03). But fasting ghrelin was also higher with resistant starch (2769 vs 2062 pg/mL; P=0.03), while postprandial ghrelin suppression (40–44%) did not differ significantly.
Resistant starch feeds gut bacteria and raises beneficial short-chain fatty acids, but the higher fasting ghrelin—a hunger hormone—is counterintuitive and could raise questions about appetite effects.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In a small 4-week study, healthy adults took 30 grams of resistant starch daily or a placebo. Resistant starch seemed to improve how well insulin helped clear sugar.
Research results
Clamp insulin sensitivity was higher with resistant starch: 9.7 vs 8.5 (absolute difference 1.2 x 10^-2 units; P=0.03). Meal-test insulin sensitivity was 33% higher relative (P=0.05). Insulin-adjusted glucose clearance was 44% higher relative (P=0.03). Fasting ghrelin was higher (2769 vs 2062 pg/mL; P=0.03).
What this means - more context
This was a 4-week study in only 10 healthy people, so the results are preliminary. The absolute difference in clamp insulin sensitivity was 1.2 x 10^-2 units, but the study did not report how this changes a person's absolute risk of diabetes or other outcomes. The 33% and 44% figures are relative differences, not absolute risk reductions. The clinical importance is unclear from the abstract.
To study the effects of resistant starch on insulin sensitivity and tissue metabolism.
In 10 healthy subjects, 4-wk supplementation with 30 g/d resistant starch vs placebo was associated with higher clamp-derived insulin sensitivity (absolute difference 1.2 x 10^-2 mg glucose/kg/min per mU insulin/L; P=0.03), 33% higher relative insulin sensitivity during a meal tolerance test (P=0.05), and 44% higher relative insulin-adjusted forearm muscle glucose clearance (P=0.03) despite lower insulin concentrations (P=0.02). Adipose tissue NEFA and glycerol release were lower (P=0.02 and 0.05), short-chain fatty acid concentrations and adipose acetate uptake were higher, and fasting ghrelin was higher (2769 vs 2062 pg/mL; P=0.03). Systemic NEFA concentrations and postprandial ghrelin suppression did not differ significantly. Authors conclude resistant starch has potential to improve insulin sensitivity; further studies in insulin-resistant persons are needed.
Methods Used
4-wk supplementation with 30 g resistant starch/d vs placebo in 10 healthy subjects; assessed by euglycemic-hyperinsulinemic clamp, meal tolerance test, and arteriovenous difference methods. Randomization and blinding not specified in abstract.
Main Finding
Resistant starch supplementation improved several insulin-sensitivity and tissue-metabolism measures in healthy adults. The clamp-derived insulin sensitivity absolute difference was 1.2 x 10^-2 units (9.7 vs 8.5; P=0.03). Meal-test insulin sensitivity was 33% higher relative (P=0.05), and insulin-adjusted glucose clearance was 44% higher relative (P=0.03). Absolute clinical risk reduction was not reported.
Confidence Level
Limited - based on abstract only, full methodology not available; very small sample (n=10), short duration (4 weeks), and randomization/blinding not specified in abstract.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Very small sample size (n=10)
- •Randomization and blinding not specified in abstract; short 4-week duration and healthy subjects only
Practical Takeaways
No dietary change can be confidently recommended from this abstract alone. If you're considering resistant starch supplements for metabolic health, discuss it with a clinician—especially if you take diabetes medication.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 537 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Lower probability
on the GRADE evidence scale
This study tested whether eating resistant starch changes how well the body uses insulin. It was a small experiment with 10 healthy people, but because we don't know if people were randomly assigned to treatments, we can only say it might be linked to better insulin sensitivity, not that it definitely causes it.
Strengths
- Placebo-controlled comparison
- Used euglycemic-hyperinsulinemic clamp
- Assessed arteriovenous differences
Weaknesses
- Full methodology not available - based on abstract only
- Randomization not explicitly stated
- Blinding not reported
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In a small 4-week study, healthy adults took 30 grams of resistant starch daily or a placebo. Resistant starch seemed to improve how well insulin helped clear sugar.
Research results
Clamp insulin sensitivity was higher with resistant starch: 9.7 vs 8.5 (absolute difference 1.2 x 10^-2 units; P=0.03). Meal-test insulin sensitivity was 33% higher relative (P=0.05). Insulin-adjusted glucose clearance was 44% higher relative (P=0.03). Fasting ghrelin was higher (2769 vs 2062 pg/mL; P=0.03).
What this means - more context
This was a 4-week study in only 10 healthy people, so the results are preliminary. The absolute difference in clamp insulin sensitivity was 1.2 x 10^-2 units, but the study did not report how this changes a person's absolute risk of diabetes or other outcomes. The 33% and 44% figures are relative differences, not absolute risk reductions. The clinical importance is unclear from the abstract.
To study the effects of resistant starch on insulin sensitivity and tissue metabolism.
In 10 healthy subjects, 4-wk supplementation with 30 g/d resistant starch vs placebo was associated with higher clamp-derived insulin sensitivity (absolute difference 1.2 x 10^-2 mg glucose/kg/min per mU insulin/L; P=0.03), 33% higher relative insulin sensitivity during a meal tolerance test (P=0.05), and 44% higher relative insulin-adjusted forearm muscle glucose clearance (P=0.03) despite lower insulin concentrations (P=0.02). Adipose tissue NEFA and glycerol release were lower (P=0.02 and 0.05), short-chain fatty acid concentrations and adipose acetate uptake were higher, and fasting ghrelin was higher (2769 vs 2062 pg/mL; P=0.03). Systemic NEFA concentrations and postprandial ghrelin suppression did not differ significantly. Authors conclude resistant starch has potential to improve insulin sensitivity; further studies in insulin-resistant persons are needed.
Methods Used
4-wk supplementation with 30 g resistant starch/d vs placebo in 10 healthy subjects; assessed by euglycemic-hyperinsulinemic clamp, meal tolerance test, and arteriovenous difference methods. Randomization and blinding not specified in abstract.
Main Finding
Resistant starch supplementation improved several insulin-sensitivity and tissue-metabolism measures in healthy adults. The clamp-derived insulin sensitivity absolute difference was 1.2 x 10^-2 units (9.7 vs 8.5; P=0.03). Meal-test insulin sensitivity was 33% higher relative (P=0.05), and insulin-adjusted glucose clearance was 44% higher relative (P=0.03). Absolute clinical risk reduction was not reported.
Confidence Level
Limited - based on abstract only, full methodology not available; very small sample (n=10), short duration (4 weeks), and randomization/blinding not specified in abstract.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Very small sample size (n=10)
- •Randomization and blinding not specified in abstract; short 4-week duration and healthy subjects only
Practical Takeaways
No dietary change can be confidently recommended from this abstract alone. If you're considering resistant starch supplements for metabolic health, discuss it with a clinician—especially if you take diabetes medication.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 537 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Lower probability
on the GRADE evidence scale
This study tested whether eating resistant starch changes how well the body uses insulin. It was a small experiment with 10 healthy people, but because we don't know if people were randomly assigned to treatments, we can only say it might be linked to better insulin sensitivity, not that it definitely causes it.
Strengths
- Placebo-controlled comparison
- Used euglycemic-hyperinsulinemic clamp
- Assessed arteriovenous differences
Weaknesses
- Full methodology not available - based on abstract only
- Randomization not explicitly stated
- Blinding not reported
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study used good tests to measure insulin sensitivity, but it only included 10 people for 4 weeks, and we don't have all the details about how it was run. That means the results are interesting but not strong enough to trust completely.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
32 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=10)+1.0/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 537 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. Randomization and blinding are not explicitly stated in the abstract. The study is small (n=10), short (4 weeks), and abstract-only, so confounding cannot be ruled out. Therefore, cause-effect relationships cannot be established.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding statement was present in the provided text, so potential conflicts cannot be assessed.
The provided text is an abstract without a COI or funding declaration; no author affiliations or disclosures are included.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Physionic cite this study, drawing 0 claims from it.
No specific claims extracted from this video yet.
Authored by
5 researchersIf this is your work, this is how we attribute it on Fit Body Science. M. Denise Robertson is listed as the lead author.